Search

Your search keyword '"Liza M. Reifler"' showing total 2 results
Start Over Author "Liza M. Reifler" Journal journal of the american heart association: cardiovascular and cerebrovascular disease
2 results on '"Liza M. Reifler"'

1. Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter‐Defibrillators in the Cardiovascular Research Network

Author

Robert T. Greenlee, Alan S. Go, Pamela N. Peterson, Andrea E. Cassidy‐Bushrow, Charles Gaber, Romel Garcia‐Montilla, Karen A. Glenn, Nigel Gupta, Jerry H. Gurwitz, Stephen C. Hammill, John J. Hayes, Alan Kadish, David J. Magid, David D. McManus, Deborah Multerer, J. David Powers, Liza M. Reifler, Kristi Reynolds, Claudio Schuger, Param P. Sharma, David H. Smith, Mary Suits, Sue Hee Sung, Paul D. Varosy, Humberto J. Vidaillet, and Frederick A. Masoudi

Subjects
arrhythmia, implantable cardioverter‐defibrillator, inappropriate shock, outcomes research, sudden cardiac death, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

BackgroundPrimary prevention implantable cardioverter‐defibrillators (ICDs) reduce mortality in selected patients with left ventricular systolic dysfunction by delivering therapies (antitachycardia pacing or shocks) to terminate potentially lethal arrhythmias; inappropriate therapies also occur. We assessed device therapies among adults receiving primary prevention ICDs in 7 healthcare systems. Methods and ResultsWe linked medical record data, adjudicated device therapies, and the National Cardiovascular Data Registry ICD Registry. Survival analysis evaluated therapy probability and predictors after ICD implant from 2006 to 2009, with attention to Centers for Medicare and Medicaid Services Coverage With Evidence Development subgroups: left ventricular ejection fraction, 31% to 35%; nonischemic cardiomyopathy

Published
2018
Full Text
View/download PDF

2. Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter‐Defibrillators in the Cardiovascular Research Network

Author

Alan H. Kadish, Stephen C. Hammill, Frederick A. Masoudi, Alan S. Go, Claudio Schuger, Romel Garcia-Montilla, David D. McManus, Liza M. Reifler, Deborah Multerer, Andrea E. Cassidy-Bushrow, Paul D. Varosy, Param P. Sharma, David J. Magid, Mary Suits, Karen A. Glenn, Robert T. Greenlee, Jerry H. Gurwitz, Sue Hee Sung, John J. Hayes, Charles Gaber, J. David Powers, Pamela N. Peterson, David H. Smith, Nigel Gupta, Kristi Reynolds, and Humberto Vidaillet

Subjects
Male, Time Factors, medicine.medical_treatment, 030204 cardiovascular system & hematology, Arrhythmias, Centers for Medicare and Medicaid Services, U.S, Ventricular Function, Left, Sudden cardiac death, Ventricular Dysfunction, Left, 0302 clinical medicine, Heart Rate, Risk Factors, 030212 general & internal medicine, Original Research, Quality and Outcomes, Medical record, Middle Aged, Implantable cardioverter-defibrillator, 3. Good health, Defibrillators, Implantable, inappropriate shock, Primary Prevention, Treatment Outcome, Cohort, Female, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, Electric Countershock, implantable cardioverter‐defibrillator, arrhythmia, sudden cardiac death, outcomes research, 03 medical and health sciences, medicine, Humans, Aged, Retrospective Studies, business.industry, Retrospective cohort study, Arrhythmias, Cardiac, medicine.disease, United States, Death, Sudden, Cardiac, Emergency medicine, Antitachycardia Pacing, Outcomes research, business, Medicaid, Catheter Ablation and Implantable Cardioverter-Defibrillator, Health Services and Outcomes Research
Abstract

Background Primary prevention implantable cardioverter‐defibrillators (ICDs) reduce mortality in selected patients with left ventricular systolic dysfunction by delivering therapies (antitachycardia pacing or shocks) to terminate potentially lethal arrhythmias; inappropriate therapies also occur. We assessed device therapies among adults receiving primary prevention ICDs in 7 healthcare systems. Methods and Results We linked medical record data, adjudicated device therapies, and the National Cardiovascular Data Registry ICD Registry. Survival analysis evaluated therapy probability and predictors after ICD implant from 2006 to 2009, with attention to Centers for Medicare and Medicaid Services Coverage With Evidence Development subgroups: left ventricular ejection fraction, 31% to 35%; nonischemic cardiomyopathy Conclusions In this community cohort of primary prevention patients receiving ICD, therapy delivery varied across demographic and clinical characteristics, but did not differ meaningfully for Centers for Medicare and Medicaid Services Coverage With Evidence Development subgroups.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results